This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jazirehi, A. R. Articles by Bonavida, B. Search for Related Content PubMed PubMed Citation Articles by Jazirehi, A. R. Articles by Bonavida, B.

Adriamycin Sensitizes the Adriamycin-resistant 8226/Dox40 Human Multiple Myeloma Cells to Apo2L/Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated (TRAIL) Apoptosis¹

Department of Microbiology, Immunology, and Molecular Genetics [A. R. J., C-P. N., X-H. G., B. B.] and Department of Medicine [G. S.], UCLA School of Medicine, University of California at Los Angeles, Los Angeles, California 90095-1747

The newly discovered member of the tumor necrosis factor superfamily, Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), has been identified as an apoptosis-inducing agent in sensitive tumor cells but not in the majority of normal cells, and hence it is of potential therapeutic application. However, many tumor cells are resistant to Apo2L/TRAIL-mediated apoptosis. Various chemotherapeutic drugs have been shown to sensitize tumor cells to members of the tumor necrosis factor family. However, it is not clear whether sensitization by drugs and sensitivity to drugs are related or distinct events. This study examined whether an Adriamycin-resistant multiple myeloma (MM) cell line (8226/Dox40) can be sensitized by Adriamycin (ADR) to Apo2L/TRAIL-mediated apoptosis. Treatment with the combination of Apo2L/TRAIL and subtoxic concentrations of ADR resulted in synergistic cytotoxicity and apoptosis for both the parental 8226/S and the 8226/Dox40 tumor cells. Adriamycin treatment modestly up-regulated Apo2L/TRAIL-R2 (DR5) and had no effect on the expression of Fas-associated death domain, c-FLIP, Bcl-2, Bcl_xL, Bax, and IAP family members (cIAP-1, cIAP-2, XIAP, and survivin). The protein levels of pro-caspase-8 and pro-caspase-3 were not affected by ADR, whereas pro-caspase-9 and Apaf-1 were up-regulated. Combination treatment with Apo2L/TRAIL and ADR resulted in significant mitochondrial membrane depolarization and activation of caspase-9 and caspase-3 and apoptosis. Because ADR is shown to sensitize ADR-resistant tumor cells to Apo2L/TRAIL, these findings reveal that ADR can still signal ADR-resistant tumor cells, resulting in the modification of the Apo2L/TRAIL-mediated signaling pathway and apoptosis. These in vitro findings suggest the potential application of combination therapy of Apo2L/TRAIL and subtoxic concentrations of sensitizing chemotherapeutic drugs in the clinical treatment of drug-resistant/Apo2L/TRAIL-resistant multiple myeloma.

This article has been cited by other articles:

				J. Jin, H. Liu, C. Yang, G. Li, X. Liu, Q. Qian, and W. Qian Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation Mol. Cancer Ther., May 1, 2009; 8(5): 1387 - 1397. [Abstract] [Full Text] [PDF]

				J. N. Shin, Y. W. Seo, M. Kim, S.-Y. Park, M.-J. Lee, B. R. Lee, J.-W. Oh, D.-W. Seol, and T.-H. Kim Cisplatin Inactivation of Caspases Inhibits Death Ligand-induced Cell Death in Vitro and Fulminant Liver Damage in Mice J. Biol. Chem., March 18, 2005; 280(11): 10509 - 10515. [Abstract] [Full Text] [PDF]

				A. R. Jazirehi, S. Huerta-Yepez, G. Cheng, and B. Bonavida Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) Inhibits the Constitutive Nuclear Factor-{kappa}B Signaling Pathway in Non-Hodgkin's Lymphoma B-Cell Lines: Role in Sensitization to Chemotherapeutic Drug-induced Apoptosis Cancer Res., January 1, 2005; 65(1): 264 - 276. [Abstract] [Full Text] [PDF]

				A. R. Jazirehi, M. I. Vega, D. Chatterjee, L. Goodglick, and B. Bonavida Inhibition of the Raf-MEK1/2-ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin's Lymphoma B Cells by Rituximab Cancer Res., October 1, 2004; 64(19): 7117 - 7126. [Abstract] [Full Text] [PDF]

				S.-H. Kim, K. Kim, J. G. Kwagh, D. T. Dicker, M. Herlyn, A. K. Rustgi, Y. Chen, and W. S. El-Deiry Death Induction by Recombinant Native TRAIL and Its Prevention by a Caspase 9 Inhibitor in Primary Human Esophageal Epithelial Cells J. Biol. Chem., September 17, 2004; 279(38): 40044 - 40052. [Abstract] [Full Text] [PDF]

				A. M. Evens, S. Prachand, B. Shi, M. Paniaqua, L. I. Gordon, and R. B. Gartenhaus Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent Clin. Cancer Res., February 15, 2004; 10(4): 1481 - 1491. [Abstract] [Full Text] [PDF]

				A. R. Jazirehi and B. Bonavida Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis Mol. Cancer Ther., January 1, 2004; 3(1): 71 - 84. [Abstract] [Full Text]

				A. R. Jazirehi, X.-H. Gan, S. De Vos, C. Emmanouilides, and B. Bonavida Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis Mol. Cancer Ther., November 1, 2003; 2(11): 1183 - 1193. [Abstract] [Full Text] [PDF]

				A. Spencer, S.-L. Yeh, K. Koutrevelis, C. Baulch-Brown ;, N. Mitsiades, C. Mitsiades, K. C. Anderson, and S. P. Treon TRAIL-induced apoptosis of authentic myeloma cells does not correlate with the procaspase-8/cFLIP ratio Blood, September 26, 2002; 100(8): 3049 - 3050. [Full Text] [PDF]